HR
Hawkins Richard J
董事长兼首席执行官
C-suiteM
内部人交易记录
首席执行官基于 3 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
Explore the complete record of transactions filed by Hawkins Richard J, 董事长兼首席执行官. Insider active across 5 companies, notably Savara Inc. In total, 21 disclosures have been logged. Split: 7 buys · 0 sell. Total volume traded: €134k. History available since 13 December 2021. The latest transaction was disclosed on 9 December 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Hawkins Richard J
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
40,000 股0Common StockSEC:0001193125-25-316315:0
5,860 股@ US$1.467.9% 占其流量Common StockSEC:0001193125-25-284702:0
48,225 股@ US$2.04499.6% 占其流量Common StockSEC:0000950170-25-088895:0
40,000 股0Common StockSEC:0000950170-24-136780:0
753,093 股Common StockSEC:0001126234-24-000122:0
4,000 股@ US$1.49923.2% 占其流量Common StockSEC:0000950170-24-107008:0
6,285 股@ US$1.354332.9% 占其流量Common StockSEC:0000950170-24-106605:0
4,902 股@ US$2.0439.9% 占其流量Common StockSEC:0000950170-24-057453:0
4,500 股@ US$2.8410.8% 占其流量Common StockSEC:0001126234-24-000035:0
690 股@ US$3.011.7% 占其流量Common StockSEC:0001126234-24-000015:0
22,500 股0Common StockSEC:0001209191-23-058844:0
10,841 股@ US$0.8288.4% 占其流量Common StockSEC:0001209191-23-058353:0
1,522 股@ US$3.314.2% 占其流量Common StockSEC:0001126234-23-000049:0
1 股@ US$1,000.004.0% 占其流量Series F Preferred StockSEC:0001209191-23-016526:0
4,500 股@ US$3.5213.3% 占其流量Common StockSEC:0001126234-23-000013:0
1,172 股@ US$0.657.8% 占其流量Common StockSEC:0001209191-22-060376:0
2,214 股@ US$8.8418.1% 占其流量Common StockSEC:0001126234-22-000105:0
541 股@ US$8.654.2% 占其流量Common StockSEC:0001126234-22-000103:0
1,466 股@ US$9.2311.1% 占其流量Common StockSEC:0001126234-22-000032:0
4,500 股@ US$10.0236.5% 占其流量Common StockSEC:0001126234-22-000007:0
728 股@ US$0.550.4% 占其流量Common StockSEC:0001209191-21-069582:0
About Hawkins Richard J
Président-Directeur Général, Hawkins Richard J has filed 21 disclosures. In the recent filings tracked, they cover the period from 2021-12-14 to 2025-12-11, with EUR 133539 of purchases and EUR 0 of sales. They are also Chief Executive Officer of Lumos Pharma, INC., as well as Director of Savara Inc and Plus Therapeutics, INC.